Save 10% off on your first order with coupon code: PANDA10

Pandameds.Com Editorial Team

The Pandameds.Com Editorial Team is dedicated to delivering accurate, transparent and trustworthy health information to help U.S. customers access safe, affordable weight loss medications from Canada. Our team of experienced medical writers, pharmacists and industry professionals ensures every article and product page is thoroughly fact checked, clearly written & updated to reflect the latest clinical guidance.

Each piece of content undergoes a stringent editorial process referencing trusted medical sources such as FDA, Health Canada, PubMed and Mayo Clinic. While we do not provide individual medical advice, our mission is to empower readers with reliable knowledge about medications like Ozempic, Saxenda, Mounjaro, Zepbound, Wegovy and Rybelsus, focused exclusively on their role in medical weight management.

Pandameds.Com helps our readers make informed decisions about their health maintaining a transparent editorial policy and working with certified reviewers

Recent Blog Post

6Feb, 2026

Ozempic Heart Benefits vs Risks: Complete Guide

February 6, 2026|

Ozempic (semaglutide) has emerged as groundbreaking medication for cardiovascular protection in patients with type 2 diabetes and heart disease. Landmark SUSTAIN-6 trial demonstrated 26% reduction in major heart events including cardiovascular death, nonfatal myocardial infarction and nonfatal stroke. However, like all medications, Ozempic comes with considerations including common 2-3 beats per minute increase in heart [...]

6Feb, 2026

Foods to Avoid on Wegovy: High-Fat, Trigger Foods & Complete Meal Plan

February 6, 2026|

Wegovy is an approved injectable weight loss medication containing active ingredient semaglutide, a GLP 1 receptor agonist that helps control appetite, regulate blood sugar and promote significant weight loss. In STEP 1 clinical trial, adults using Wegovy pen lost an average of about 15% of their starting body weight over 68 weeks when combined with [...]

6Feb, 2026

Does Mounjaro Cause Body Aches: <1% Direct + 5-10% From Dehydration - Management Guide

February 6, 2026|

Mounjaro body aches affect fewer than 1 in 100 patients directly (uncommon myalgia), while 5-10% experience muscle pain from GI-induced dehydration and electrolyte loss during rapid weight loss. According to the SURMOUNT clinical trials, body aches are not among the primary side effects of Mounjaro (tirzepatide), yet patient reports consistently link these symptoms to magnesium [...]

5Feb, 2026

Zepbound vs Mounjaro: IDENTICAL Tirzepatide – Weight Loss vs Diabetes Branding

February 5, 2026|

If you're confused about whether to ask your healthcare provider for Zepbound or Mounjaro, here's the bottom line: they are the same drug with different brand names and FDA approvals. Both medications contain tirzepatide, a revolutionary dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that helps people lose weight by reducing appetite [...]

5Feb, 2026

Rybelsus vs Wegovy: Pill vs Pen – Wegovy 15% Loss vs Rybelsus 6 lbs

February 5, 2026|

Same semaglutide molecule, very different results. Wegovy’s once-weekly injection delivers approximately 15% body weight loss in clinical studies, while Rybelsus’s daily pill produces a more modest average of about 6 lbs over 26 weeks at its currently approved doses. The difference comes down to delivery: oral semaglutide has roughly 1% bioavailability through the stomach, whereas [...]

5Feb, 2026

Januvia vs Ozempic: Ozempic (15% Weight Loss), Januvia (2-4lbs) A1c Comparison

February 5, 2026|

When comparing Januvia vs Ozempic, the differences are significant: Ozempic (semaglutide) crushes Januvia (sitagliptin) for weight loss achieving up to 15% body weight reduction compared to Januvia's modest 2 to 4 pounds but Januvia remains substantially cheaper and causes virtually no gastrointestinal side effects. Clinical trials demonstrate Ozempic's superior A1c reduction (1.5-1.8%) compared to Januvia [...]

5Feb, 2026

Medicare Ozempic Coverage 2026: Type 2 Diabetes (Yes), Weight Loss (No) – Complete Guide

February 5, 2026|

Medicare covers Ozempic (semaglutide) for the treatment of type 2 diabetes under Part D prescription drug plans. However, Medicare does not cover Ozempic when prescribed solely for weight loss due to the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 which explicitly excludes coverage for weight loss medications. Ozempic is approved for improving blood [...]

5Feb, 2026

Mounjaro Weight Loss Timeline: What to Expect Week by Week

February 5, 2026|

Mounjaro users typically lose 3-5 lbs in their first month, reach 15% body weight reduction by month 12, and can achieve up to 21% loss by week 72-making it one of the fastest-acting GLP-1 weight loss medications available today. According to the SURMOUNT-1 trial published in The New England Journal of Medicine, participants taking tirzepatide [...]

5Feb, 2026

Trulicity vs Wegovy: Wegovy 15% Weight Loss vs Trulicity 7 lbs – Diabetes vs Obesity Drugs

February 5, 2026|

Wegovy delivers approximately 15% body weight loss in clinical trials-dramatically outperforming Trulicity’s average weight reduction of about 7–10 lbs (3–5% of body weight). Both are GLP-1 receptor agonists administered as once-weekly injections, yet Wegovy produces roughly 2.5 times greater weight loss results than Trulicity. This makes the choice between these injectable medications heavily dependent on [...]

Go to Top
X